Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049399 · ClinicalTrials.gov registry record · NA
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
A NA study of Progressive Supranuclear Palsy, sponsored by Noscira.
- Completed
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT01049399 is a NA study of Progressive Supranuclear Palsy that has completed, run by Noscira. The registered enrollment target is 146 participants, below the 444-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT01049399, a NA study of Progressive Supranuclear Palsy, has completed, sponsored by Noscira.
- COMPLETED
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
Conditions Studied
Interventions
- DRUG placebo
- DRUG tideglusib
Study Locations (20)
Other
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson Beelitz - Beelitz-Heilstätten
- Humboldt Universitat Charite, Campus Virchow, Neurologisch - Berlin
- Universitatsklinikum Carl-Guslav-Carus, Technische Universitat Dresden, Klinik und Poliklinik fur Neurologie - Dresden
- Medizinische Hochschule Hannover, Neurologie 0E 7210 - Hanover
- Zentrum fur Nervenheilkunde. Klinik fur Neurologie mit Poliklinik. - Marburg
- University Hospital Tuebingen,Eberhard-Karls-Universitat, Universitatsklinikum Neurologie - Tübingen
- Hospital de Cruces - Barakaldo
- Dpto.neurologia. H. Clinic. - Barcelona
- Hospital de Donostia - Donostia / San Sebastian
- Dpt. Neurologia. Hospital Ramón y Cajal. - Madrid
- Hospital U. La Paz - Madrid
- Hospital Mutua Terrassa - Terrassa
California
- The Parkinson's and Movement Disorder Institute - Fountain Valley
- Department of Neurology, David Geffen School of Medicine at UCLA - Los Angeles
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of South Florida 5 - Tampa
Kentucky
- Division of Movement Disorders, University of Louisville - Louisville
New Jersey
- University of Medicine and Dentistry, Robert Wood Johnson Medical School - New Brunswick
Barcelona
- Fundació Ace - Barcelona
Madrid
- Hospital Puerta del Hierro - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049399
The ClinicalTrials.gov registry entry for NCT01049399 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (67% lower). The listed sponsor is Noscira, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01049399 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01049399 about?
NCT01049399 is a clinical study titled "Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy". The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
What is the current status of trial NCT01049399?
This trial is currently completed. It is a NA study. The enrollment target is 146 participants. The study started on 2009-12. Estimated completion is 2011-11.
What conditions does trial NCT01049399 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy.
What interventions are being tested in trial NCT01049399?
The interventions under investigation include: placebo (DRUG), tideglusib (DRUG).
Who is sponsoring clinical trial NCT01049399?
This trial is sponsored by Noscira, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049399 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, New Jersey, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
RECRUITING · NA
-
Art Therapy in Progressive Supranuclear Palsy
ACTIVE NOT RECRUITING · NA
-
Community Outreach for Palliative Engagement -- Parkinson Disease
ACTIVE NOT RECRUITING · NA
-
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
ACTIVE NOT RECRUITING · NA
-
In-Home Care for Patients With PSP and Related Disorders
COMPLETED · NA
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.